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Fluid biomarkers in clinical trials of 
Alzheimer’s disease therapeutics
Aaron Ritter* and Jeffrey Cummings
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
With the demographic shift of the global population toward longer life expectancy, the 
number of people living with Alzheimer’s disease (AD) has rapidly expanded and is pro-
jected to triple by the year 2050. Current treatments provide symptomatic relief but do 
not affect the underlying pathology of the disease. Therapies that prevent or slow the 
progression of the disease are urgently needed to avoid this growing public health emer-
gency. Insights gained from decades of research have begun to unlock the pathophysiol-
ogy of this complex disease and have provided targets for disease-modifying therapies. 
In the last decade, few therapeutic agents designed to modify the underlying disease 
process have progressed to clinical trials and none have been brought to market. With 
the focus on disease modification, biomarkers promise to play an increasingly important 
role in clinical trials. Six biomarkers have now been included in diagnostic criteria for AD 
and are regularly incorporated into clinical trials. Three biomarkers are neuroimaging 
measures  –  hippocampal atrophy measured by magnetic resonance imaging (MRI), 
amyloid uptake as measured by Pittsburg compound B positron emission tomography 
(PiB-PET), and decreased fluorodeoxyglucose (18F) uptake as measured by PET (FDG-
PET) – and three are sampled from fluid sources – cerebrospinal fluid levels of amyloid 
β42 (Aβ42), total tau, and phosphorylated tau. Fluid biomarkers are important because 
they can provide information regarding the underlying biochemical processes that are 
occurring in the brain. The purpose of this paper is to review the literature regarding the 
existing and emerging fluid biomarkers and to examine how fluid biomarkers have been 
incorporated into clinical trials.
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introduction
Alzheimer’s disease (AD), the most common cause of dementia, is a progressive neurodegenerative 
disorder that becomes more prevalent with increasing age. Currently, there are more than 44   million 
people worldwide living with dementia (1). As the demographics of the global population shift 
toward longer life, it is projected that this number will be more than triple by the year 2050. With 
the estimated cost of dementia already exceeding 1% of the world’s gross domestic product (1), 
this rapid increase constitutes a looming public health emergency. Available therapies for AD were 
approved based on their ability to improve the symptoms of the disease but do not alter underlying 
pathophysiologic processes (2). In order to ease the public health burden posed by AD, drugs with 
disease-modifying properties are urgently needed.
Insights gained from decades of AD research have begun to elucidate the pathophysiology 
underlying this complex disease. It is now widely accepted that the chain of biochemical events 
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thought to be responsible for AD are triggered many years 
prior to symptom onset (3). While an enhanced understand-
ing of the two characteristic pathological changes seen in 
AD – plaques composed of amyloid β (Aβ) and neurofibrillary 
tangles (NFTs) composed of hyperphoshorylated tau  –  have 
yielded targets that may be amenable to pharmacological inter-
vention, no therapeutics with potentially disease-modifying 
properties have advanced past Phase III trials. A number 
of theories have been proposed to explain this failure: 
(1) selection of patients based on clinical diagnosis can be inaccu-
rate, leading to the inclusion of large number of patients without 
AD in clinical trials (4): (2) the timing of interventions designed 
to clear amyloid – at stages when subjects have already begun 
to manifest the symptoms of mild to moderate dementia  –  is 
too late in the disease course to affect cognitive change (5, 6): 
(3) the progression of the disease is too gradual to demonstrate 
drug–placebo differences in “typical length” drug trials (7): (4) 
candidate agents have been permitted to advance to Phase III 
trials without strong evidence of target engagement or disease 
modification from preclinical models or early clinical trials (8).
New strategies are needed to address the high failure rate in 
AD drug development. New trial designs, centralized rating and 
review, more predictive models in preclinical testing, improved 
clinical outcome measures, and more stringent testing of drugs in 
Phase II are all strategies that may improve success rates. While 
proof of efficacy of AD treatments will ultimately depend on 
demonstration of benefit on clinical measures, biological mark-
ers (biomarkers) of underlying disease processes will take on 
enhanced significance, especially as trials move toward enrolling 
subjects earlier in the disease process.
Aided by the development of biomarkers, AD is now con-
sidered one clinical disease with a continuum through several 
clinical stages (5). Reflecting this change in disease conception, 
several biomarkers have now been accepted widely enough that 
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FiGURe 1 | The amyloidogenic pathway. In the amyloidogenic pathway, 
The amyloid precursor protein (APP) is processed in two sequential steps: 
(1) in the first step, APP is cleaved by BACE1 yielding a membrane-bound 
fragment and releasing sAPP into the interstitial space. (2) In the second 
step, gamma secretase cleaves the remaining membrane-bound fragment 
releasing an abeta 42 fragment.
they have been incorporated into the two most recent research 
criteria (9–12). Three of these biomarkers are imaging biomark-
ers: hippocampal atrophy as detected by structural magnetic 
resonance imaging (MRI); decreased uptake of (18F) in charac-
teristic regions on positron emission tomography (FDG-PET); 
and increased amyloid tracer retention on PET (PiB-PET). Three 
biomarkers are cerebrospinal fluid (CSF) protein levels: low CSF 
levels of amyloid β42 (Aβ42) and elevated CSF levels of total 
(t-tau) and phosphorylated tau (p-tau). Imaging biomarkers are 
important because they can provide crucial information about 
topographical changes in the brain. There are a number of excel-
lent reviews describing their use in both clinical practice and 
drug trials (13). They will not be described here. The focus of 
this contribution is fluid biomarkers. The purpose of this paper 
is to review the literature regarding the existing and emerging 
fluid biomarkers and to examine how fluid biomarkers have been 
incorporated into clinical trials.
Fluid Biomarkers Regularly incorporated 
into Clinical Trials
CSF Aβ42
A picture of the complex chain of events leading to AD has 
emerged over the last three decades. The leading theory to 
explain the pathophysiological changes in AD is the amyloid 
cascade hypothesis (14). Based largely on models derived from 
familial cases of AD – in which, one of three autosomal domi-
nantly inherited mutations results in pathological aggregation 
and accumulation of Aβ – the amyloid cascade hypothesis posits 
that the pathological accumulation of amyloid triggers a complex 
sequence of biochemical events ultimately leading to widespread 
synaptic dysfunction, neuronal dysfunction, and cell death. An 
overview of the initial steps involved in Aβ production is pro-
vided in Figure 1.
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The amount of Aβ in the brain is determined by a balance 
between Aβ production and degradation/clearance mechanisms 
(15). Several enzymes, such as neprilysin, insulin-degrading 
enzyme, plasminogen inhibitor, break down Aβ in the interstitial 
space (16). Fragments that are not degraded in the brain are actively 
transported across the blood–brain barrier (BBB) or diffuse into 
the CSF space (17). The two transport proteins responsible for 
Aβ efflux from the brain are the low density lipoprotein receptor 
related protein-1 (LRP-1) and Apo J (15). Once in blood, Aβ is 
rapidly taken up by plasma proteins and transported to the liver 
for further degradation. A dynamic equilibrium exists between 
the amount of Aβ in the CSF and the amount of Aβ in the plasma 
space, and a small amount of non-neuronal Aβ is found in the 
CSF. A transport protein known as the receptor for advanced 
end products (RAGE) is responsible for the influx of Aβ from 
the serum into the CNS. The amount of amyloid in the brain is a 
highly regulated process and it is estimated that the entire load of 
soluble Aβ is turned over twice per day (17).
In AD, there is a significant decrease in Aβ clearance (18) 
resulting in dramatic increases (100–1,000 fold) in the amount 
of Aβ in the brain (17). Aβ fragments consisting of 42 amino 
acids (Aβ42) are particularly prone to aggregation (19). As 
amyloid concentrations rise, Aβ42 fragments rapidly aggre-
gate into oligomers of various sizes and conformations (20). 
Aβ oligomers are neurotoxic and have been shown to inhibit 
memory, disrupt long-term potentiation, and impair synaptic 
function in animal models (21, 22). Emerging data is begin-
ning to clarify the role that Aβ oligomers play in triggering AD 
pathophysiology (23). In addition to oligomerizing, Aβ frag-
ments also fibrillize into cross-β-sheets, forming the insoluble 
plaques that constitute the main neuropathological finding in 
AD. The primary role of amyloid plaques seems to be to serve 
as large reservoirs of soluble amyloid (the amount of insoluble 
fibrillar Aβ is 100-fold greater than the amount of soluble Aβ 
in the brain) (24). Plaques may serve to buffer any changes 
in the amount of circulating amyloid. Plaques, however, are 
not entirely benign species as array tomography has revealed 
that they are surrounded by a ring of dystrophic and disfigured 
neurons (25), implying that they exert local neurotoxic effects 
(26). Plaque burden, however, correlates poorly with disease 
severity (27, 28) and it is now widely thought that Aβ’s primary 
role in the pathogenesis of AD is by triggering another patho-
logical process (29).
Several commercially available, CSF enzyme-linked immu-
nosorbent assays (ELISAs) have been developed that detect CSF 
Aβ. CSF assays for Aβ detect soluble monomeric species. In 
AD, levels of CSF Aβ 40 remain stable while Aβ42 levels have 
consistently been shown drop to <50% of normal (30). The 
reduction in CSF Aβ42 levels is generally thought to reflect both 
the sequestration of Aβ42 in insoluble plaques (27) and aggre-
gation into oligomeric species (31). Post-mortem studies have 
also reported correlations between low CSF Aβ42 and increased 
amyloid plaque load (32, 33). With the development of amyloid 
PET imaging (which allows for the direct visualization of fibril-
lar amyloid), the relationship between low CSF Aβ42 levels and 
amyloid plaque has been established in vivo (34) and has been 
confirmed in many different studies (35, 36). Although low CSF 
Aβ42 levels and increased fibrillar uptake on PET scan generally 
correspond with one another and are often used interchangeably 
to diagnose AD, it is important to note that they are not detect-
ing the same form of amyloid (CSF assays detect monomeric, 
soluble amyloid while PET imaging detects fibrillar plaque). 
The discrepancy between the two measures has been illustrated 
in several studies (37, 38). A recent study using cross-sectional 
data found that 20% of cognitively normal subjects had low CSF 
Aβ42 levels but negative PET scans. This discrepancy was seen 
in only 6% of subjects with dementia (38). PET scan positivity 
was also found to correlate closely with increased CSF tau levels. 
The authors interpreted these findings to suggest that CSF Aβ42 
“positivity” comes earlier in the disease progression than amy-
loid uptake on PET scan. If this finding is verified in longitudinal 
studies, it would suggest that low levels of CSF Aβ42 may be a 
marker of early disease processes while amyloid scanning would 
have utility as a marker of disease progression.
CSF Tau
Neurofibrillary tangles composed of hyperphosphorylated tau are 
the second major neuropathologic finding in AD. Tau is a ubiqui-
tous intracellular protein that promotes cellular stability through 
interactions with microtubule proteins (39). Consequently, tau 
plays a key role in maintaining neuronal integrity, cellular signal-
ing, and axonal transport. The dynamic relationship that exists 
between tau and microtubule proteins is driven by the phospho-
rylation state of tau, which is under the control of a variety of 
kinases and phosphatases (40, 41). In AD, for reasons that remain 
to be elucidated, the phosphorylation state of tau increases (42). 
Various theories have been proposed to explain this phenom-
enon. A leading theory is that it is a direct response to the toxic 
effects of Aβ accumulation (43); however, other potential causes 
include neuroinflammation (44), oxidative stress (45), genetic 
factors (46), or even infection (47). Tau hyperphosphorylation is 
a key step in the pathogenesis of AD because hyperphorsphoryl-
ated tau no longer binds to microtubule proteins (48). This leads 
to higher cytosolic concentrations of unbound tau. Unbound, 
hyperphosphorylated tau is susceptible to aggregation, protein 
trapping, and misfolding (49, 50). Aggregated fibrils consisting of 
hyperphosphorylaed tau comprise the helical filaments in NFTs. 
The accumulation of NFTs within neuronal axons is toxic to cells. 
Both the loss of normal physiological function (i.e., loss of cellular 
integrity) and the gain of toxicity induced by NFT accretion are 
thought to contribute to neuronal dysfunction in AD (50).
In AD, NFT accumulation proceeds through the brain in a 
stereotypical pattern, appearing first in the locus coeruleus and 
the entorhinal cortex, proceeding next to the hippocampus, and 
then spreading to the temporal cortex and neocortical association 
areas (51). Neuropathological studies have reported correlations 
between NFT formation and neuronal loss, both of which increase 
in parallel with AD disease progression (52). Understanding the 
intercellular spread of NFT as it progresses through the brain 
has been the focus of recent investigation (53, 54). In mouse 
models, injection of filamentous tau induces NFT formation at 
the injection site that over time progresses to neighboring and 
synaptically connected brain regions (55). This finding suggests 
that tau exhibits prion-like behavior as it spreads from highly 
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focal brain regions to involvement of limbic, paralimbic, and 
neocortical regions (56).
In AD, CSF levels of t-tau increase to 3× normal (57). Increases 
in CSF t-tau have been associated with both NFT burden and 
Braak staging (33). Elevations in CSF t-tau, however, are not spe-
cific to AD as transient elevations are found following stroke (58) 
and traumatic brain injury (TBI) (59). This finding suggests that 
elevated CSF t-tau levels are reflective of non-specific neuronal 
injury and cell death. The highest levels of CSF t-tau are found 
in Creutzfeldt–Jakob disease (CJD), a disease characterized by 
accelerated neurodegeneration (60). It is also important to note 
that tau secretion is an active physiological process, occurring 
independently of neuronal injury (56). In AD, an additional 
source of CSF tau is the residence of this molecule in extracellular 
space during its passage from neuron to neuron. More research 
is needed to fully understand the composition of CSF t-tau levels 
in AD.
In addition to detecting total tau (t-tau), several ELISAs have 
been developed that reflect the phosphorylation state of tau. In 
AD, CSF levels of p-tau increase to approximately twice normal 
levels. Commonly used assays measure tau phosphorylation at 
residue either 181 or 231, both of which increase to similar levels 
in AD (61). Autopsy studies reveal that CSF p-tau correlates with 
NFT burden in AD (62). Because levels of p-tau are thought 
to reflect both NFT load and phosphorylation state, elevations 
in p-tau are generally thought to be a more specific finding in 
AD than elevations in CSF t-tau (61, 63). Dissociations between 
high t-tau and normal p-tau levels have been reported in several 
dementing diseases including CJD (64), frontotemporal demen-
tia, and vascular dementia (61).
Utility of CSF Aβ42, t-Tau, and p-Tau
Used individually, CSF markers (CSF Aβ42 or tau) demonstrate 
good sensitivity in distinguishing subjects with AD from non-
controls (41); however, several studies have reported poor speci-
ficity in distinguishing subjects with AD from non-AD dementias 
(65–67). Diagnostic precision has also been shown to decrease 
with increasing age (68). Diagnostic accuracy increases consid-
erably when these measures are combined into a so-called “AD 
signature” consisting of low Aβ42 and elevated total and p-tau. 
This signature demonstrates 80–95% sensitivity and specificity in 
identifying subjects with AD in the dementia phase of disease (5) 
and has been shown to be highly predictive of AD pathology at 
autopsy (28). The ability of CSF biomarkers to identify subjects 
harboring AD pathology is considerably better than the accuracy 
of a diagnosis made on clinical grounds alone. In a study looking 
at 919 autopsy-confirmed cases of AD that comprise the National 
Alzheimer’s Coordinating Center (NACC) database, clinical diag-
nosis was 71–88% sensitive but only 44–71% specific in predicting 
AD pathology at autopsy (69). The challenge of accurately iden-
tifying subjects with AD pathology based on clinical diagnosis 
alone has also been demonstrated in clinical trials that have incor-
porated amyloid PET scans (4, 70, 71). Data from several clinical 
trials suggest that a substantial percentage of subjects enrolled in 
clinical trials do not actually have evidence of AD pathology on 
PET scan. For example, in the Phase III trial of bapineuzumab 
>35% of APOE ε4 non-carriers had negative amyloid scans (70). 
As it is unlikely that compounds with putative anti-AD properties 
will produce clinical benefits in subjects without AD pathology, 
inaccurate inclusion rates increase the likelihood of trial failure. 
Incorporating CSF biomarkers into inclusion criteria is a strat-
egy that can be used to enrich patient samples, increase a trial’s 
statistical power, and ensure that candidate compounds are being 
accurately tested against the AD substrates they are designed to 
ameliorate.
The temporal relationship among Aβ42, t-tau, and p-tau levels 
has been the subject of much exploration and several models 
have been proposed to explain the complex dynamics that exist 
between CSF biomarkers and disease progression (43, 72). There 
is now convincing evidence that CSF Aβ42 and tau levels convert 
from normal to “pathologic” years before the onset of clinical 
symptoms, providing a powerful tool to assess which individuals 
are at risk for developing AD dementia (73). Decreases in CSF 
Aβ42 are typically appreciated before changes in CSF tau, and 
in accordance with the amyloid cascade hypothesis, suggest that 
amyloid accumulation drives tau pathology. Examining a cohort 
of subjects with autosomal dominant AD, Bateman et al. dem-
onstrated that changes in Aβ42 can be fully appreciated 25 years 
before expected symptom onset and changes in tau 15  years 
before expected symptoms onset (3). In cohorts without AD 
mutations, several studies have reported that decreases in CSF 
Aβ42 (with or without changes in CSF tau) can be detected in 
cognitively normal subjects and predict the development of cog-
nitive decline (74) and dementia (75, 76). CSF biomarkers have 
also showed good sensitivity (83–95%) and specificity (71–90%) 
in predicting which subjects with mild cognitive impairment 
(MCI) will progress to develop AD dementia (77–80). The accu-
rate identification of patients in this early stage of the disease 
is important because MCI is a non-specific syndrome and only 
around 50% of subjects with MCI are thought to have AD (81). 
Using CSF biomarkers to accurately identify subjects harboring 
AD pathology as early as possible in the disease course will allow 
for testing of candidate compounds earlier in the disease course 
and at time points that may prove more amenable to pharmaco-
logical intervention.
While the CSF biomarkers discussed above provide a powerful 
window into the pathological processes occurring in AD, several 
limitations deserve mention. An innate limitation of all fluid 
biomarkers is that they lack anatomical precision (82). Unlike 
imaging biomarkers, CSF biomarkers do not provide insight 
into the topographic distribution of pathological changes in 
the brain. Another limitation of current CSF biomarkers is that 
aside from small increases in t-tau (83), they remain fairly stable 
during the dementia phase of disease (84). Therefore, current CSF 
biomarkers have limited utility in disease staging or prognosis 
(73). Furthermore, because only weak associations between CSF 
biomarkers and clinical measures have been reported (85), it is 
unknown if drug-induced changes in these measures will result 
in clinically meaningful effects (16). Unknown variables include 
when interventions need to be timed and to what degree a bio-
marker change may be correlated with a clinical outcome (86). 
An additional limitation of CSF biomarkers is the high degree 
of variability and lack of assay standardization that exists among 
laboratories. A 2013 study analyzing data from Alzheimer’s 
TABLe 1 | Candidate CSF biomarkers.
Biomarker Role in the pathogenesis of AD evidence for clinical utility
CSF BACE1 Transmembrane secretase responsible for the 
rate-limiting step in the generation of amyloid
Increased CSF BACE in AD in some (94) but not all studies (209)
Increased CSF BACE levels predicted which subjects with MCI progressed to dementia (96)
CSF sAPP Byproduct of BACE activity Increased CSF levels in MCI (98), AD (99), and incipient AD (100)
Elevated CSF levels were not predictive of subjects converting from MCI to dementia (79)
CSF Aβ oligomers Neurotoxic species that inhibit memory,  
long-term potentiation, and synaptic function
Low levels make detection difficult (103, 104) (105)
Inverse correlation between CSF Aβ oligomers and MMSE score (104, 105)
CSF Aβ38 Aβ fragment consisting of 38 amino acids Increased CSF levels do not correlate with amyloid uptake on PET scan (110)
CSF levels did not discriminate between healthy controls and subjects with AD (111)
CSF visinin-like 
protein-1 (VILIP-1)
Neuronal calcium sensor protein that  
functions in membrane trafficking
CSF VILIP-1 levels correlated with elevated CSF t-tau and p-tau and decreased brain 
volumes (115)
Elevated CSF levels predicted cognitive decline in subjects with MCI (117)
CSF F2-isoprostanes Markers of lipid peroxidation caused by free 
radicals
Increased CSF levels in AD (121)
Increased CSF levels predicted cognitive decline in MCI (122)
Increased CSF levels improved diagnostic accuracy when combined with MRI and memory 
testing (123)
YLK-40 Marker of plaque-associated neuroinflammation 
secreted by activated microglia
Elevated CSF levels in early AD (126)
Elevated CSF levels predicted cognitive decline in MCI (127)
Neurogranin Synaptic protein involved in plasticity and  
long-term potentiation
Elevated CSF levels in AD but not MCI (130)
Elevated CSF levels predict conversion from MCI to AD and predicted a more rapid rate of 
decline in subjects with MCI and a positive amyloid PET scan (131)
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Association quality control program reported a 20–30% discrep-
ancy among laboratories in measuring CSF biomarkers (68). This 
is too high for globally accepted reference ranges to be assigned 
(87). Quality control and standardization projects have been ini-
tiated with the intent of improving precision and reproducibility 
across laboratories (5).
emerging CSF Biomarkers
Given the limitations of the currently used CSF biomarkers, 
substantial research has been devoted to finding and validating 
additional CSF biomarkers. Guided by an enhanced understand-
ing of the neurobiological changes in AD, several promising 
candidate markers have been identified. Table 1 summarizes the 
development of CSF candidates.
Amyloid-Related CSF Biomarker Candidates
BACe1
BACE1 is an aspartic protease that catalyzes the rate-limiting 
step in the generation of Aβ42 (Figure  1). BACE1 also plays 
a role in the processing of other membrane proteins, such as 
neuregulin (88), and is thought to influence myelination (89) 
and synaptic plasticity (90). Because of its diverse and important 
role in normal brain functioning, BACE1 activity is synchro-
nized by a variety of complicated regulatory mechanisms at 
both the transcriptional and translational levels (91). Increased 
levels of BACE1 and indicators of BACE1 activity have been 
found in the brains of patients with AD (92, 93). Elevations in 
CSF BACE1 have also been detected in the CSF of patients with 
AD (94, 95) and subjects with MCI who later went on to develop 
AD (96). Several explanations have been proposed to account 
for the increases in CSF BACE1 in AD. Increased CSF BACE1 
levels have been found to correlate with increases in CSF t-tau 
(96) and one possibility is that BACE1 release into the CSF is 
a product of a non-specific release of proteins from injured or 
dying neurons. New research, however, suggests a more compli-
cated picture, in which, normal regulatory controls on BACE1 
activity are lost. Faghihi et al., for example, has reported that a 
non-coding antisense RNA that stabilizes BACE1 mRNA and 
results in increased BACE1 activity is increased in the brains 
of subjects with AD. Furthermore, in vitro exposure of cells to 
Aβ42 induces this antisense RNA, laying the groundwork for 
a deleterious feed-forward cycle of AD disease progression, in 
which, increased levels of Aβ induce the expression of increased 
BACE1 activity and further Aβ production (97). CSF BACE1 will 
be important in establishing target engagement in compounds 
with putative BACE1 inhibiting properties.
sAPP-β
The first step in APP processing is the proteolytic cleavage by 
BACE1. This cleavage yields two products, one of which is the 
membrane bound fragment (which then undergoes further pro-
cessing by gamma secretase to eventually form Aβ) and the other, 
a larger amino acid fragment, sAPP-β, which is secreted into the 
interstitial space. Levels of CSF sAPP-β may serve as an indirect 
marker of BACE activity and Aβ production. Studies looking at 
the clinical correlation between CSF sAPP-β have generally been 
positive and elevated levels of sAPP-β have been reported in MCI 
(98), AD (99), and patients with incipient AD (100). However, not 
all studies have demonstrated meaningful clinical correlations 
(79). Changes in CSF levels of sAPP-β may eventually be used 
in clinical trials to provide evidence of target engagement and to 
monitor for drug effects.
Aβ Oligomers
In  vitro exposure of Aβ oligomers to hippocampal neurons 
quickly impairs synaptic function and is more toxic than 
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exposure to monomeric or fibrillar forms of amyloid (101). This 
finding, in conjunction with reports from several animal models 
that demonstrate neuroanatomical and behavioral abnormalities 
before the appearance of plaques (25), has led the field to consider 
the role of Aβ oligomers in AD pathogenesis. The steady state of 
Aβ oligomers in the CSF is very low – <0.02% of total CSF Aβ 
levels (102) – and attempts to detect them standard assays have 
failed (101) while other attempts have produced variable results 
(103–105). Recently, Hong et al. were able to demonstrate that 
Aβ oligomers in the interstitial fluid were quickly sequestered 
onto cellular membranes, displaying a particular affinity for GM1 
gangliosides (102). In this study, Aβ oligomers demonstrated a 
higher binding affinity for cell membranes than monomeric Aβ 
species, potentially explaining the low contribution of oligomers 
to the overall composition of CSF Aβ levels. The authors were 
also able to detect low levels of GM1-bound Aβ in human CSF. 
These levels correlated with CSF Aβ42. Further investigation is 
needed to determine if CSF GM1-bound Aβ will prove useful as 
a biomarker in AD. It is also important to note that soluble Aβ oli-
gomers may have utility as a progression biomarker, as two stud-
ies – one using flow cytometry (105) and the other using ELISA 
(104)  –  have reported an inverse correlation between levels of 
CSF Aβ oligomers and score on MMSE. The challenges of reliably 
quantifying Aβ oligomers in CSF will need to be overcome before 
the potential of this biomarker can be fully realized.
Aβ isoforms
While most Aβ species exist as peptide fragments consisting of 
either 40 or 42 amino acids, isoforms of varying length have also 
been detected in the CSF of patients with AD (106–108). One 
small study reported that a particular CSF amyloid “signature” 
consisting of Aβ16, Aβ33, Aβ39, and Aβ42 could distinguish 
subjects with AD from controls with an accuracy of 86% (106). 
The performance of Aβ38 has been investigated in a number 
of studies and as an exploratory measure in a phase II trial of 
avagacestat (109). The utility of CSF Aβ38 appears to be limited 
given that levels do not correlate with amyloid uptake on PET 
(110) and did not discriminate controls from subjects with AD 
in another study (111).
Non-Amyloid CSF Biomarker Candidates
Cerebrospinal fluid markers that reflect processes that occur 
after amyloid deposition, including neurodegeneration, synapse 
loss, neuroinflammation, oxidative stress, etc. may also provide 
diagnostic and prognostic utility. A select group of candidates 
will be discussed here. For a comprehensive review, the reader is 
directed to the review by Fagan and Perrin (112).
visinin-Like Protein-1
Visinin-like protein-1 (VILIP-1) is a neuronal calcium sensor 
protein that can be detected in most regions of the brain (sparing 
the caudate and putamen) (113). It belongs to a family of proteins 
thought to play a role in membrane trafficking (Braunewell Cell 
Tissue Res) and is thought to play a role in calcium-mediated 
neuronal death (114). CSF levels of VILIP-1 have shown to 
correlate with CSF t-tau, p-tau, and brain volumes (115, 116). 
High levels of CSF VILIP-1 have also been reported to predict 
the cognitive decline in a cohort of patients with mild AD 
followed over a period of 2.6  years (117). Several studies have 
shown that higher levels of CSF VILIP-1 are seen in AD than 
other dementing diseases, such as dementia with Lewy bodies 
(114), frontotemporal dementia, and progressive supranuclear 
palsy (117).
F2-isoprostanes
There is a growing body of evidence suggesting that oxida-
tive damage plays a key role in the pathogenesis of AD (118). 
F2-isoprostanes are markers of lipid peroxidation caused by free 
radicals (119). Increased levels of F2-isoprostanes are found in AD 
brains (120) and in the CSF of patients with AD (121). Elevated 
levels of CSF F2-isoprostanes have also been shown to correlate 
with eventual cognitive decline in MCI (122) and improve diag-
nostic accuracy of AD when combined with memory testing and 
MRI (123).
YKL-40
Neuropathological, biochemical, and genetic studies indicate 
that alterations in neuroinflammatory pathways play a role in 
the pathogenesis of AD (124). YKL-40 is a marker of plaque-
associated neuroinflammation that is secreted by activated 
microglia (125). Several studies suggest that YKL-40 may be an 
early marker of AD as levels have been shown to be increased in 
the preclinical phase (116, 126) and to predict cognitive decline 
in early stage dementia (127).
Neurogranin
Neurogranin is a synaptic protein that is enriched in forebrain 
areas (128). It is thought to be involved in synaptic plasticity and 
long-term potentiation (129). Elevated levels of neurogranin have 
been reported in the CSF of subjects with AD (but not MCI) 
(130). Elevated levels of CSF neurogranin have been shown to 
predict conversion from MCI to AD and to predict a more rapid 
rate of decline in subjects with MCI and a positive amyloid PET 
scan (131).
Serum Biomarkers
The process of obtaining CSF fluid by lumbar puncture (LP) 
is invasive and associated with a small but significant risk of 
post-LP headache (132). Given the negative public perception 
of the LP procedure, it is unlikely that all patients in a clinical 
trial would agree to have CSF sampling. Serum samples are easily 
obtained and readily accepted by patients. The development of 
a reliable serum biomarker could potentially be integrated into 
a multi-stage screening and diagnostic process, to provide valu-
able information about which patients should proceed to more 
expensive/invasive testing, and to monitor disease progression 
(133). Currently, there has been little success in finding reliable 
serum biomarkers in AD or MCI (41). Table 2 summarizes the 
findings regarding candidate serum biomarkers in AD.
Serum Aβ
Despite being the focus of intense investigation, the utility of 
serum Aβ as AD biomarkers has not been fully defined. Serum 
TABLe 2 | Candidate non-CSF biomarkers.
Biomarker Role in the pathogenesis of AD evidence for clinical utility 
Serum Aβ40 Major byproduct of APP processing Associated with increased risk of AD dementia in some but not all studies (134, 135)
Serum Aβ42 Primary component amyloid plaques Associated with increased risk of AD dementia in some but not all studies (136)
Serum tau NFTs composed of hyperphosphorylated 
tau comprise major neuropathological 
finding in AD
Undetectable by traditional assays (148)
Ultra-sensitive assays have detected and report increased levels in AD compared to normal but with 
considerable overlap; do not discriminate between subjects with MCI who remained stable and those 
who progressed to AD (150)
August 2015 | Volume 6 | Article 1867
Ritter and Cummings Fluid biomarkers in Alzheimer’s disease
Frontiers in Neurology | www.frontiersin.org
Aβ (40,42) levels in AD show considerable overlap with non-AD 
controls, which limits its use as a diagnostic marker (92). The use 
of serum Aβ as a marker of risk is also unclear as some studies 
have reported an increased risk with increased Aβ40 (134, 135) or 
Aβ42 (136) while others have reported that increased risk is asso-
ciated with low levels of Aβ42 (137). In addition, several studies 
have failed to find an association between serum Aβ levels and AD 
risk (138, 139). One meta-analysis reported that a low Aβ42:Aβ40 
ratio was associated with an increased risk of AD (140); however, 
the generalizability of this analysis is limited by the heterogeneity 
of included studies. Little is known about the prognostic value of 
serum levels of Aβ. One study has reported that higher baseline 
levels of serum Aβ42 were associated with faster rates of cognitive 
decline over a 1-year period in subjects with AD (141). The small 
sample size and the lack of follow-up analysis of plasma levels 
means that additional research is needed to determine if serum 
levels can be used for patient stratification. Changes in serum Aβ 
levels have also been detected in several clinical trials and have 
been used as evidence to support claims of target engagement (71, 
142). Further investigation is needed to clarify the association 
between serum Aβ levels and AD pathophysiology.
One potential explanation for the discrepancy between the 
performance of CSF Aβ and serum Aβ is that serum levels do not 
accurately reflect CSF Aβ levels (143). The majority of CSF Aβ is of 
neuronal origin and is thought to directly reflect Aβ production in 
the brain. Serum Aβ, on the other hand, is derived from a variety 
of non-neuronal sources including the liver, bone, muscle, kidney, 
pancreas, and platelets (66). The physiologic milieu in the CSF 
is also drastically different from the serum compartment. In the 
serum, there are 300× more Aβ binding proteins than in the CSF 
(15) and the majority of Aβ in the serum is protein bound (144).
Serum Tau
Transient elevations in serum tau are detected in response to 
neuronal injury from ischemic stroke (145), hypoxic brain injury 
during cardiac arrest (146), and TBI (147). There is considerable 
evidence that the biochemical regulation of tau is dependent on 
which biological compartment it resides. For example,  follow-
ing neuronal injury, CSF tau may stay elevated for weeks while 
in the serum, tau is cleared rapidly, returning to normal levels 
within hours (58). As a result, serum tau levels are not thought to 
accurately reflect CSF tau levels. In a small study using a sandwich 
ELISA, serum tau levels were essentially undetectable in patients 
with AD despite having elevated CSF t-tau levels (148). More 
recently, ultra-sensitive assays have been developed that have cap-
tured changes in serum tau levels following TBI (146) and cardiac 
arrest (149). This assay has been tested in one cohort with AD 
(150). In this study, higher serum tau levels were seen in patients 
with AD as compared to subjects with MCI and controls; however, 
a considerable degree of overlap was noted across the three groups, 
limiting its diagnostic utility (150). Additionally, serum tau levels 
did not discriminate between subjects with MCI who remained 
stable and those with MCI who went on to develop AD.
Other Serum Markers
Other novel serum targets for development include 
F2-isoprostanes (151) and plasma complement factor H (152); 
however, the results of studies looking at these candidates have 
been disappointing and do not support their application as diag-
nostic or prognostic factors at this time.
Proteomic Approaches
An alternative approach to developing serum biomarkers in AD 
is to identify a characteristic profile of protein markers, which, 
taken together, would constitute a pathological “fingerprint” 
(133). Significant interest in proteomic strategies was generated 
following a study, which identified a characteristic pattern of 18 
abnormal plasma signaling and inflammatory proteins in a sample 
of patients with AD (153). Applied to a pre-existing data set, this 
profile correctly identified subjects with AD from healthy controls 
with 90% accuracy. In addition, this profile predicted conversion 
from MCI to dementia in 20 of 22 patients (followed up to 6 years). 
With advances in bioinformatics, the numbers of trials employing 
proteomic approaches have increased. Using pre-existing data 
sets, a number of proteomic profiles have been identified, which 
have shown high diagnostic accuracy (154–157). Challenges to 
the proteomic approach include successful replication of findings 
across studies (154) and whether profiles can reach appropriate 
standardization levels to be replicated across laboratories (133). 
Guidelines designed to approach these challenges have recently 
been published (158). No consensus has been reached on a spe-
cific proteomic profile that provides reliable information in AD.
Urine and Saliva
Urine and saliva are appealing targets for biomarker develop-
ment due to their ease of collection. Molecules sampled from 
these sources, however, are subjected to filtration and metabolic 
processing and may not reflect biochemical changes occurring 
in the brain. For this reason, AD research has largely ignored 
these biological compartments (159). One small study detected 
reduced acetylcholinesterase activity in the saliva of patients with 
AD compared to normal controls (160) while another found no 
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difference (161). Increased levels of salivary Aβ42 have been dem-
onstrated in patients with mild AD compared to normal controls 
and patients with Parkinson’s disease (162). In another study using 
mass spectroscopy, an increased salivary p-tau to t-tau ratio was 
found in AD patients compared to normal controls (163). More 
research is needed on these readily accessible fluids to determine 
if they contain meaningful information on brain states.
Use of Fluid Biomarkers in Clinical Trials
The scope of use of fluid biomarkers in clinical trials is described 
below. Here, we describe the results of several clinical trials in 
which fluid biomarkers were included among outcome measures. 
Table 3 summarizes the results of these studies as well as others 
that are not described.
Active Amyloid immunization Strategies
The impetus for the development of amyloid immunotherapy 
strategies came from a landmark study involving the PDAPP 
transgenic mouse, which overexpresses mutant human APP. In 
this study, it was shown that amyloid plaque deposition could be 
prevented by immunizing mice against Aβ42 (164). Subsequent 
studies reported that active immunization attenuated memory 
changes and reduced behavioral impairment (165, 166). Testing 
in several different models revealed that the greatest benefit was 
seen when immunization was achieved before the expected age 
of amyloid deposition (164, 167), signifying that immunization 
strategies work best in a clearance paradigm (167).
Composed of a full-length synthetic Aβ42 molecule, AN1792 
was the first anti-amyloid vaccine evaluated in clinical trials. 
Despite appearing safe and demonstrating efficacy on an explora-
tory measure of functional decline in Phase I (168), further 
development of AN1792 was halted after 6% of subjects devel-
oped meningoencephalitis during Phase II testing (169). While 
the exact cause of this response remains unknown, the type of 
T-cell response (Th2-biased in the Phase I study and Th1-biased 
in the Phase II study) differed between the two studies (170). 
Treatment was terminated early (only 20% developed the prede-
termined antibody response), but double-blind assessments were 
continued during the entire 12-month period. Antibody response 
TABLe 3 | Fluid biomarkers in clinical trials.
Compound Mechanism of action Relevant clinical outcome Fluid biomarker outcome
AN1792 Active immunization against full-
length Aβ42
PII: halted because of the development of 
meningoencephalitis (169)
PII: reduction in CSF tau; no change in CSF Aβ42 (169)
CAD106 Active immunization against Aβ 
fragment
PI: well tolerated in subject with AD (176) PI: no changes in CSF Aβ40, Aβ42, p-tau, or t-tau; increase in 
total serum plasma Aβ and decrease in free Aβ (176)
Bapineuzumab Monoclonal antibody directed 
against N-terminus of Aβ
PII: post hoc analysis showed effect on 
cognition in APOE ε4 non-carriers (185)
PII: reduction in CSF p-tau and t-tau; no effect on CSF Aβ40 or 
42 (186)
PIII: two separate studies (one with APOE 
ε4 carriers and one with non-carriers) 
failed to reach clinical endpoints (70)
PIII: decrease in CSF p-tau (carriers); no effect on any CSF 
measures (Aβ42, p-tau, t-tau) in non-carriers; no effect on Aβ42 
in carriers (70)
Development of MRI changes in ~20% of 
treated patients (210)
Solanezumab Monoclonal antibody against 
middle portion of Aβ
PIII: two large trials failed to reach clinical 
endpoints. A pooled analysis of the two 
trials demonstrated an effect on cognition 
in subjects with mild dementia (142)
PII: increase in serum and CSF Aβ40 and 42 (190)
PIII: increase in both CSF Aβ40 and 42; no effect on CSF p-tau 
or t-tau; increases in serum Aβ40 and 42 (142)
Crenezumab Monoclonal antibody against 
middle portion of Aβ; built on 
IgG1 backbone
PI: well tolerated in subjects with mild to 
moderate AD (211)
PI: increase in serum Aβ levels (211)
Gantenerumab Entirely humanized monoclonal 
antibody binds the N-terminus of 
Aβ fibrils
PIII: results not yet published, trial 
discontinued
No fluid biomarker data have been reported
Ponezumab Humanized monoclonal antibody 
binds the C-terminus of Aβ
PI: well tolerated in subjects with AD 
(212–214)
PI: increase in serum and CSF Aβ levels w/single dose (212)
Tramiprosate Molecule that binds Aβ and 
prevents aggregation
PIII: no benefit on clinical endpoints (215) PII: reduction in CSF Aβ42 (216)
Avagacestat Gamma secretase inhibitor PII: well tolerated at low doses; at doses 
found to have CSF effects, a trend 
worsening cognition was detected (109)
PII: at higher, poorly tolerated doses, reductions in CSF Aβ 
38, 40, and 42 were reported. Non-significant trend toward 
reduction in CSF p-tau and t-tau at all doses
No changes in CSF Aβ at lower doses (109)
Semagacestat Gamma secretase inhibitor PIII: preplanned analysis showed an 
association with worsening cognitive and 
functional outcomes resulting in early 
termination (71)
PII: no effect on CSF Aβ40 or 42; reduction in plasma Aβ40 
(201)
PI: dose-dependent reduction in Aβ production as measured by 
SILK (18)
PIII: no changes in CSF Aβ or t-tau; p-tau remained the same 
(increased in placebo) dose-dependent reduction in serum Aβ40 
and 42 (71)
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was associated with two positive clinical effects: improvement 
on composite scores of memory function and, in an extended 
follow-up study, significantly less functional decline (171). CSF 
monitoring in a subset of 11 subjects deemed “antibody respond-
ers” showed significant reductions in CSF t-tau (−204 ± pg/mL) 
at 1 year. Changes in CSF Aβ42 levels were not appreciated (169).
Several post-mortem neuropathological studies have been 
completed on subjects receiving the AN1792 vaccine (172–175). 
Because of the small number of participants and lack of infor-
mation about baseline (or pretreatment) plaque burden, it is 
difficult to make definitive conclusions about these studies (8). 
Nonetheless, several interesting findings have been reported 
including reductions in plaque load (174) and decreased micro-
glial activation (173). Evidence of pathological change was not, 
however, associated with improvement in survival time or time 
to severe dementia (174). Only one study (examining five brains) 
reported evidence of a reduction in tau pathology (175).
It is difficult to make accurate assessments regarding the CSF 
and neuropathological data from the AN1792 trials given the 
small sample sizes and the heterogeneity of the reported findings. 
According to the amyloid hypothesis, an active immune response 
would likely only be beneficial if achieved prior to the event that 
triggers the cascade (29). From a fluid biomarker perspective, it is 
unknown if the dramatic changes in CSF t-tau had any association 
with the positive signal seen on several clinical metrics. This is 
one of many unanswered questions that remain after this trial. 
Clearly, additional study is required to fully inform decisions 
about whether active immunization strategies can be efficacious 
in the treatment or prevention of AD. Several vaccines designed to 
illicit a safer B-cell response, including ACC-001, CAD106, V950, 
and Affitope AD02, are in various stages of clinical testing (86). 
The results of both Phase I and IIa testing have been published 
for CAD106 (176, 177). Although the vaccine appears much safer 
than AN1792, neither study demonstrated a significant biomarker 
or clinical effect.
Passive Amyloid immunization Strategies
Passive immunization strategies involve the infusion of human-
ized monoclonal antibodies designed to bind amyloid species. 
Preclinical studies have shown that passively administered anti-
bodies can enter the CNS and bind to various forms of amyloid 
(178). Compounds in this class differ depending on what domain 
within the Aβ fragment they bind (179).
Bapineuzumab
Bapineuzumab is a humanized monoclonal antibody directed 
against the N-terminus of Aβ. Recognition of the N-terminus 
ensures that bapineuzumab can attach to both soluble and 
insoluble amyloid species. Several theories have been proposed 
to explain bapineuzumab’s mechanism of action including direct 
inhibition of plaque formation (180) and antibody-mediated 
triggering of microglial cells to clear plaques (181). In preclini-
cal models, bapineuzumab-treated PDAPP mice show reduced 
cortical amyloid plaque burdens (178). As with other amyloid 
therapies, treatment with bapineuzumab appears most effective 
for preventing rather than clearing pre-existing plaques (6). One 
potential explanation for the inability of bapineuzumab to clear 
existing plaques is proposed by Demattos et al. who hypothesize 
that in advanced disease, bapineuzumab is unable to bind plaques 
because it is saturated by soluble amyloid species that surround 
mature plaques (182). Infusion of bapineuzumab has also been 
associated with an increased incidence of microhemorrhage, 
which is thought to be due to its binding to vascular amyloid (183).
A Phase II study was undertaken to assess the safety of 
bapineuzumab in subjects with mild to moderate AD dementia 
(184). Higher rates of edema known as amyloid-related imaging 
abnormalities (ARIA) were seen at higher infusion doses and in 
subjects possessing the APOE ϵ4 genotype. Although clinical 
benefits were not initially detected, a post hoc analysis using mul-
tiple comparisons suggested possible benefits on both cognition 
and function (185). The biomarker data from Phase II testing also 
detected a possible disease-modifying signal as CSF data (n = 27) 
showed significant reductions in p-tau (−9.9 pg/mL) and a trend 
toward reduction in t-tau (−72.3  pg/mL) (186). In a smaller 
trial using an identical protocol, change in amyloid uptake as 
measured by PET scan was assessed as a primary outcome. In 
this trial, treatment with bapineuzumab (N = 20) was associated 
with reduced cortical binding compared with baseline (4).
Based on the positive signals seen in the Phase II trials, bap-
ineuzumab advanced to Phase III testing (9). To reduce the risk 
of ARIA-E, dose selection was based on APOE ϵ4 status. Included 
in the secondary analysis was amyloid PET, volumetric MRI, 
and CSF biomarkers. Results of this study were disappointing 
as primary endpoints were not met. Although there were some 
signs of a positive biomarker effect, the signal was much weaker 
in Phase III testing than had been seen in the Phase II trial. APOE 
ϵ4 carriers (N = 127) experienced significant but small reductions 
in CSF p-tau (−5.8 pg/mL) compared to the placebo compari-
son group. In non-carriers, significant reductions in CSF p-tau 
were reported but only at the highest dose (−8.17 pg/mL). No 
significant changes were noted in CSF Aβ42 levels or t-tau levels. 
In both APOE ϵ4 carriers and non-carriers, amyloid uptake (as 
measured by PET scan) remained unchanged during the course 
of the trial.
The interpretation of outcome data from the bapineuzumab 
trials is complicated by the finding that a significant percentage of 
participants (6% of APOE ϵ4 carriers and 36% of APOE ϵ4 non-
carriers) did not have evidence of amyloid pathology on PET scan. 
Nonetheless, the reduction of CSF p-tau is notable and suggests 
that passive immunization strategies targeting amyloid may be able 
to effect key pathological processes. Additional studies are needed 
to replicate this finding. The preclinical data suggest that bapineu-
zumab may be more effective when timed earlier in the disease 
course or at higher doses (182). The candidacy of bapineuzumab, 
however, is limited by ARIA-E.
Solanezumab
Solanezumab is a humanized monoclonal antibody directed 
against the middle amino acid section of Aβ. Because this 
epitope is not accessible on amyloid plaques, solanezumab only 
binds soluble Aβ species and does not bind Aβ plaques (187) or 
oligomers (188). In mouse models, infused solanezumab rapidly 
binds and completely sequesters plasma Aβ (187). By capturing 
the entire pool of soluble Aβ, solanezumab prevents this pool 
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of amyloid from re-entering the brain, potentially shifting the 
amyloid gradient toward plaque dissolution and efflux out of 
the brain (29). According to this hypothesis, solanezumab acts 
as a “peripheral sink” as it draws amyloid out of the brain. In 
mouse models, peripheral administration of solanezumab results 
in rapid, 1,000-fold increases in plasma Aβ and significant 
reductions in plaque deposition (187). Not all preclinical data on 
solanezumab has been positive as one study found that treatment 
neither prevented nor reduced amyloid deposition (189). Unlike 
bapinezumab, solanezumab has not been associated with ARIA-E 
in either preclinical or human testing.
In a Phase II testing, treatment with solanezumab was associ-
ated with dose-related increases in both plasma and CSF levels of 
Aβ40 and 42 (190). Notably, both antibody-bound and antibody-
free levels of CSF Aβ42 increased. Increases in unbound CSF 
Aβ42 could be interpreted as evidence of Aβ42 leaving plaques 
and diffusing down the gradient to replace sequestered plasma Aβ 
species consistent with the peripheral sink hypothesis. Amyloid 
PET scanning would have been informative in determining if the 
source of the increased unbound Aβ42 was in fact from plaque.
Solanezumab advanced to two large Phase III trials known as 
EXPEDITION 1 and 2 (142). Although both trials failed to meet 
primary endpoints, identical study designs allowed for pooling of 
data across the two studies. In the pooled analysis, the subgroup 
identified as having mild AD showed statistically significant 
slower rates of cognitive decline and positive trends on functional 
measures (185). Consistent with the Phase II trial, serum levels 
of both Aβ40 and 42 increased following infusion and remained 
significantly elevated during the entire trial. In a smaller subset of 
patients with CSF data (N = 44), significant increases were seen 
in both total CSF Aβ40 and 42, but unlike the Phase II trial, there 
were no significant changes in unbound Aβ42. Treatment was 
also not associated with changes in CSF tau, volumetric MRI, or 
amyloid PET.
Any interpretation of outcome data from the Phase III study of 
solanezumab must be tempered by the finding that a significant 
percentage (>20%) of enrollees who underwent amyloid PET 
scanning during the trial had negative scans (29). The dramatic 
increases in both serum and CSF levels of Aβ species in those 
treated with solanezumab could be interpreted as evidence of 
amyloid mobilization in the CNS. Whether antibody-mediated 
sequestration of soluble amyloid is enough to drive deposited 
amyloid out of plaque is still unknown and was not demonstrated 
in this trial with PET scanning (187). Clearly, the preclinical 
evidence regarding solanezumab has suggested a more profound 
effect on amyloid plaque prevention than clearance, and, as 
with other anti-amyloid therapies, treatment may prove more 
effective earlier in the disease course. Two ongoing trials of 
solanezumab – one enrolling patients with mild AD and the other 
enrolling cognitively subjects – will hope to shed light on these 
lingering issues.
Gamma Secretase inhibitors
Gamma secretase is a multi-unit enzyme complex that facilitates 
the second enzymatic step in the processing of APP to Aβ. It con-
sists of four subunits: nicastrin, presenilin-1 (PSEN1), anterior 
pharynx-defective-1, and presenilin-2 (PSEN2). Mutations in 
the genes that code for PSEN1 or PSEN2 cause early-onset AD 
by increasing the fractional production of Aβ42 (27). In animal 
models, compounds that decrease gamma secretase activity have 
been shown to reduce Aβ42 synthesis and improve behavioral 
and cognitive symptoms (191, 192). Development of safe gamma 
secretase inhibitors is complicated by the enzyme’s crucial role in 
the regulation of Notch protein signaling pathways. Notch signal-
ing is involved in cell fate pathways in rapidly dividing cells and 
disruption of normal Notch protein function can result in adverse 
gastrointestinal, hematologic, and dermatologic effects (193). 
Safe gamma secretase inhibitors must show a selective preference 
for Aβ inhibition over disruption of Notch signaling pathways.
Semagacestat
Semagacestat is a gamma secretase inhibitor that demonstrates 
selective inhibition of APP processing over Notch inhibition in 
several in vitro studies (194, 195). Not all studies have reported 
this preference, and in the most recent study (published after 
the Phase III trials were completed) semagacestat showed greater 
affinitiy for inhibiting Notch signaling pathways than BACE 
(196). In animal models, semagacestat reduces soluble Aβ in 
brain, CSF, and serum. Because studies using microdialysis show 
significant reductions in interstitial amyloid, there was also hope 
that gamma secretase inhibition would drive the amyloid gradi-
ent and promote the dissolution of amyloid out of plaques and 
into the interstitial space (197). Data from several mouse models 
suggested that although gamma secretase reduced soluble Aβ 
levels and prevented the formation of new plaques, there was 
little evidence that treatment promoted the clearance of pre-
existing plaques (198, 199).
Early human testing of semagacestat was enriched by the use 
of stable isotope labeling kinetics (SILK) (18). By continuously 
labeling and monitoring soluble Aβ in the CSF, SILK provides an 
estimation of the production and clearance of Aβ over a specified 
period of time (200). Using SILK, it was shown that single doses 
of semagacestat caused dramatic reductions in Aβ production 
in healthy human subjects. This finding provided convincing 
evidence of target engagement and semagacestat advanced to 
additional testing. In a 14 week Phase II study powered to detect 
safety, treatment was associated with significant reductions in 
serum Aβ40, but somewhat surprisingly, not with significant 
changes in either CSF Aβ40 or Aβ42 (post hoc analyses suggested 
a trend toward CSF Aβ40 reduction) (201).
Two large multicenter trials enrolling more than 2,000 
patients have been conducted (71). Known as the IDENTITY 
1 and IDENTITY 2, both trials were terminated early after 
a preplanned interim analysis revealed that treatment was 
associated with an increased incidence of adverse side effects. 
Patients receiving active treatment experienced skin cancers, 
GI symptoms, and dermatological side effects at twice the rate 
of those receiving placebo. In the modified intention-to-treat 
population, treatment was associated with worsening cognition 
and functional status. Biomarker from IDENTIY included both 
serum and CSF biomarkers as well as neuroimaging. Significant 
dose-dependent reductions in both serum Aβ40 and 42 were seen 
with treatment. Notably, the reduction in serum Aβ40 was more 
than twice that seen for Aβ42. CSF monitoring of Aβ (40,42) and 
Clinical Measure AD Pathology
Biomarker 
Outcome
Drug Placebo 
Difference
FiGURe 2 | Standard parallel group design to demonstrate disease 
modification groups receiving active treatment and placebo would be 
compared on clinical measures while an effect on disease pathology 
would be demonstrated by showing differences on a biomarker 
measure of disease progression. A correlation between drug–placebo 
difference and a biomarker outcome could potentially support a claim of 
disease modification.
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tau was done in a smaller subset of patients (N = 47). Although 
no significant changes were seen in either Aβ or t-tau, there 
was a significant reduction in p-tau levels, which was greater in 
the lower dose group (8% vs. 4%). Changes in amyloid uptake 
were not appreciated in 59 patients with multiple amyloid PET 
scans. Worsening cognition and an increased rate of side effects 
were also seen in Phase II testing of avagacestat, another gamma 
secretase inhibitor (109).
Unless gamma secretase inhibitors without Notch signal-
ing inhibition can be developed (and definitively proven 
in  vitro), it is unwise to devote further resources to gamma 
secretase inhibition as a viable treatment for AD. Inhibition of 
Aβ production, however, remains a promising option for AD 
therapies. Biomarker data from the semagacestat trial, which 
showed significant (albeit, modest) reductions in CSF p-tau 
levels, may indicate that reducing Aβ production may alter the 
neuropathological process of AD. An alternative pathway to 
reduce Aβ production is with BACE1 inhibition. Several lines of 
research support the role of BACE1 activity in the pathogenesis 
of AD including two studies that have reported allelic varia-
tions, that reduce BACE1 activity, are protective against AD 
(202, 203). A significant barrier to BACE1 inhibitor develop-
ment is that its large active site requires the development of 
bulky compounds that do not pass through the BBB into the 
brain (204). Nonetheless, several BACE1 inhibitors have been 
developed and are entering clinical testing. Preliminary data 
suggest that BACE1 inhibitors significantly reduce CSF Aβ42 
levels (205).
Conclusion
Aided by the development of several validated biomarkers, the 
concept of AD has drastically changed over the past 30  years. 
Reflected in new research criteria, AD is now seen as a disease 
that progress through several stages (ranging from a prodromal/
asymptomatic stage to mildly symptomatic to frank dementia) (5). 
We now know that the biological processes that lead to the disease 
are triggered years to decades before the onset of symptoms (9). 
Fluid biomarkers, which provide a window into the complex 
biochemical process in the brain, will take on an enhanced role 
in overcoming the challenges of developing therapeutic agents 
with disease-modifying properties. Three CSF fluid biomarkers 
(consisting of low Aβ42 and elevated t-tau and p-tau) are now 
widely accepted and commonly used in both clinical practice and 
research. When combined, these three biomarkers constitute an 
“AD signature” that better predicts the presence of AD pathol-
ogy on autopsy than a diagnosis made on clinical grounds (73). 
Because changes in these biomarkers can be detected years 
before the dementia phase of disease, they have also been shown 
to demonstrate good accuracy in identifying individuals at risk 
for disease progression (77). As a result, they should be used to 
enhance clinical trial enrichment strategies, especially as trials 
move toward enrolling patients earlier in the disease course. Less 
is known about their utility in tracking disease progression or 
monitoring therapeutic responses. There are some data to suggest 
that CSF tau tracks more closely with disease progression (52) 
and may be better suited in this role than Aβ. It is still unknown 
if drug-induced changes in these markers will result in clinically 
meaningful benefits.
Due to several shortcomings in the current fluid biomarkers, it 
is imperative that new biomarkers be developed. Several promis-
ing new candidates have emerged with good preliminary data to 
support their further development. These include CSF BACE1 
(96), VILIP-1, and YLK-40 (116). The matching of a biomarker 
with a particular drug designed to modulate that aspect of AD 
pathophysiology (CSF BACE1 with a BACE1 inhibitor) has 
the potential to provide information about target engagement, 
inform dosing decisions, and to monitor for drug effects. Perhaps, 
the most promising of all emerging approaches is the develop-
ment of proteomics. With further development of biotechnology 
that promises to increase the capacity to analyze larger datasets, 
it seems likely that an “AD fingerprint” composed of several fluid 
biomarkers will emerge that will enhance our ability to identify, 
stage, and maybe even chose appropriate treatments for AD.
Several candidate agents with potential disease-modifying 
properties have advanced to Phase III testing, each has failed to 
meet clinical endpoints. A few trials have included biomarker 
data as secondary outcomes. Owing to the heterogeneity of 
the findings and lack of correlation with clinical metrics, these 
results are difficult to interpret. The slow progression of the 
disease, complicated pathophysiology, and difficulty in accurately 
modeling the pathology of sporadic AD in animal models present 
formidable challenges to clinical trial design and implementation. 
Biomarkers, however, have the ability to answer questions more 
quickly and effectively about target engagement, patient selec-
tion, and disease monitoring. In preclinical studies, biomarkers 
can be used to verify that a candidate agent is having its proposed 
effect on the biological systems it is designed to target. Because 
animal models are limited in their ability to replicate all of the 
behavioral and pathological features of AD (206), testing in mul-
tiple animals may improve the predictive value of clinical testing. 
Preclinical testing should also include biomarker data that are 
translatable to humans (including both CSF and serum). CSF 
testing in larger animals like guinea pigs and canines can provide 
valuable information about a candidate drug’s effects in the CSF 
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